In mice models with incomplete metastatic melanoma resection, the combination of GENPs with anti-PD-L1 treatment in the sprayable in situ hydrogel restored the immune cell activity in spleen and DLNs, inhibited local residual tumor growth and metastasis, as well as suppressed tumor recurrence and significantly extended survival. Here, CD274 is linked to melanoma.